Trial Profile
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Cotadutide (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors MedImmune
- 01 Jul 2022 Results published in the Diabetes, Obesity and Metabolism
- 29 Jun 2021 Results assessing glycemic and renal effects of cotadutide presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 13 Apr 2020 Results published in the ClinicalTrials.gov Trial Registry